Skip to content
OpenCapital
Get started

Rigel Pharmaceuticals RIGL fostamatinib — Government contracts revenue

Similar metrics at other companies

Emergent Biosolutions logo
EBSContracts and grants — Total revenues
$6.4M-51.1%
SLD
SLDPGovernment Contract — Revenue
$134K-79.8%
XOMA Corporation logo
XOMATovorafenib — Income Not From Contract With Customer Cost Recovery Method
$2.77M-49.9%
Catalyst Pharmaceutical logo
CPRXFirdapse — Revenue
$98.86M+18.1%
Celldex Therapeutics logo
CLDXGrant — Revenue
$15K-97.7%
CRISPR Therapeutics logo
CRSPGrant — Revenue
$458K-47.1%

Other financials

Income statement

See full
Revenue$58.8M+10.3%
Gross profit$54.2M+10.8%
Operating income$11.9M-7.0%
Net income$8.7M-24.4%
EPS (diluted)$0.44-30.2%

Balance sheet

See full
Cash & equivalents$24.5M-46.6%
Total debt$68.4M+5,079%
Total equity$399.9M+2,054%
Total assets$504.6M+187%

Cash flow

See full
Operating cash flow$2.7M+405%
CapEx$73.0K—
Free cash flow-$22.0M—

Valuation

See full
Market cap$684.39M+102%
Enterprise value$728.29M+148%
P/E1.9×-7.2×
P/S2.3×+0.6×

Profitability

See full
Gross margin93.4%+3.7pp
Operating margin41.6%+19.9pp
Net margin121.5%+103pp
FCF margin-61.7%—

Returns & leverage

See full
Return on equity174.1%—
Debt / equity0.2×+0.1×
Current ratio2.6×+0.4×

Where this comes from

Reported directly by Rigel Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:GovernmentAssistanceOperatingIncome.

The official record: Rigel Pharmaceuticals’s 10-K, filed March 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rigel Pharmaceuticals's fostamatinib — government contracts revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Rigel Pharmaceuticals's fostamatinib — government contracts revenue?
Rigel Pharmaceuticals (RIGL) reported fostamatinib — government contracts revenue of $75K in Q4 2025.
What is the long-term trend for Rigel Pharmaceuticals's fostamatinib — government contracts revenue?
Over 2 years (2023 to 2025), Rigel Pharmaceuticals's fostamatinib — government contracts revenue has grown at a -47.8% compound annual growth rate (CAGR), from $1.1M to $300K.
What does fostamatinib — government contracts revenue mean?
Revenue derived specifically from government-funded research grants, development contracts, or procurement programs related to fostamatinib. This metric captures the extent to which public sector funding supports the development or distribution of the product. It serves as an indicator of non-dilutive financing and external validation of the drug's clinical utility.